Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK

Loss of the tumor suppressor NF1 leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors leads to the development of drug resistance and ultimately disease progression. To investiga...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Pucciarelli, Daniela, Angus, Steven P., Huang, Benjamin, Zhang, Chi, Nakaoka, Hiroki J., Krishnamurthi, Ganesh, Bandyopadhyay, Sourav, Clapp, D. Wade, Shannon, Kevin, Johnson, Gary L., Nakamura, Jean L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7907257/
https://ncbi.nlm.nih.gov/pubmed/32847978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-1017
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg